Inverting T-Cell Exhaustion in Hematological Malignancies
1Jinan University, Guangzhou, China
2Polish Academy of Sciences, Poznan, Poland
3Chinese Academy of Sciences, Guangzhou, China
4University of Macau, Macau, China
Inverting T-Cell Exhaustion in Hematological Malignancies
Description
T-cell immunotherapies, such as CAR-T and TCR-T-cell therapies, play an important role in treating hematological malignancies (HM), including leukemia, lymphoma, and multiple myeloma. However, T-cell senescence and exhaustion, which may be induced by tumor microenvironment or leukemia cells, limit the clinical effects of T-cell therapy.
One of the major reasons is the upregulation of T-cell inhibitory receptors (immune checkpoints), such as programmed cell death receptor-1 (PD-1), cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), T-cell immunoglobulin mucin-domain-containing-3 (Tim-3) and T-cell lymphocyte activation gene-3 (LAG-3, and similar. Significantly, immune checkpoint inhibitors can restore the anti-tumor effects of T-cells in cancer patients, however these immunotherapy effects can be inconsistent. This could be due to the heterogeneity of the immune system, but this link remains unclear.
This Special Issue aims to collect original research articles which focus on revealing the characteristics and mechanisms of T-cell senescence and exhaustion in HM, and further exploring approaches to inverse T-cell senescence and exhaustion for T-cell immunotherapy. Review articles which summarize the current advances of T-cell immunotherapy based on inversion of T-cell senescence and exhaustion of HM are also welcomed.
Potential topics include but are not limited to the following:
- Characteristics of T-cell senescence and exhaustion in patients with HM
- Influence factors of T-cell senescence in HM
- Molecular mechanism of T-cell exhaustion in HM
- Heterogeneity of immunotherapy effects based on immune checkpoint inhibitors
- T cell exhaustion inversion combining CAR-T-cell therapy
- Antibody-based therapy in HM
- Novel potential biomarkers for T-cell immunotherapy